Is FOCL or CBLL more profitable?

FocalTherics has a net margin of -41.47% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -41.47% -137.61% -40.62% CeriBell -63.51% -38.19% -30.92%

Which has better earnings and valuation, FOCL or SIBN?

SiBone has higher revenue and earnings than FocalTherics. SiBone is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FocalTherics $70.53M 2.64 -$29.25M -$0.81 N/A SiBone $206.22M 3.47 -$18.90M -$0.39 N/A

Is FOCL or SIBN more profitable?

SiBone has a net margin of -8.10% compared to FocalTherics' net margin of -41.47%. SiBone's return on equity of -9.56% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -41.47% -137.61% -40.62% SiBone -8.10% -9.56% -7.06%

Does the media refer more to FOCL or SIBN?

In the previous week, FocalTherics and FocalTherics both had 1 articles in the media. FocalTherics' average media sentiment score of 0.75 beat SiBone's score of 0.00 indicating that FocalTherics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FOCL or BBNX more profitable?

FocalTherics has a net margin of -41.47% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -41.47% -137.61% -40.62% Beta Bionics -60.27% -23.00% -20.55%

Does the media prefer FOCL or BBNX?

In the previous week, Beta Bionics had 4 more articles in the media than FocalTherics. MarketBeat recorded 5 mentions for Beta Bionics and 1 mentions for FocalTherics. Beta Bionics' average media sentiment score of 1.06 beat FocalTherics' score of 0.75 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SGP or FOCL?

Spyglass Pharma has higher earnings, but lower revenue than FocalTherics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A N/A N/A N/A FocalTherics $70.53M 2.64 -$29.25M -$0.81 N/A

FocalTherics (FOCL) Competitors

$4.96 +0.06 (+1.22%)

As of 12:19 PM Eastern

Compare

FOCL vs. CBLL, SIBN, BBNX, SGP, and TCMD

Should you buy FocalTherics stock or one of its competitors? MarketBeat compares FocalTherics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FocalTherics include CeriBell (CBLL), SiBone (SIBN), Beta Bionics (BBNX), Spyglass Pharma (SGP), and Tactile Systems Technology (TCMD). These companies are all part of the "medical equipment" industry.

How does FocalTherics compare to CeriBell?

FocalTherics (NASDAQ:FOCL) and CeriBell (NASDAQ:CBLL) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

In the previous week, FocalTherics had 1 more articles in the media than CeriBell. MarketBeat recorded 1 mentions for FocalTherics and 0 mentions for CeriBell. CeriBell's average media sentiment score of 1.87 beat FocalTherics' score of 0.75 indicating that CeriBell is being referred to more favorably in the news media.

Company	Overall Sentiment
FocalTherics	Positive
CeriBell	Very Positive

FocalTherics has a net margin of -41.47% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-41.47%	-137.61%	-40.62%
CeriBell	-63.51%	-38.19%	-30.92%

FocalTherics presently has a consensus target price of $6.00, suggesting a potential upside of 20.97%. CeriBell has a consensus target price of $22.20, suggesting a potential upside of 18.25%. Given FocalTherics' higher possible upside, research analysts plainly believe FocalTherics is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Comparatively, 20.1% of CeriBell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

FocalTherics has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.64	-$29.25M	-$0.81	N/A
CeriBell	$95.07M	7.49	-$53.41M	-$1.63	N/A

Summary

CeriBell beats FocalTherics on 9 of the 16 factors compared between the two stocks.

How does FocalTherics compare to SiBone?

FocalTherics (NASDAQ:FOCL) and SiBone (NASDAQ:SIBN) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

SiBone has higher revenue and earnings than FocalTherics. SiBone is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.64	-$29.25M	-$0.81	N/A
SiBone	$206.22M	3.47	-$18.90M	-$0.39	N/A

62.7% of FocalTherics shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 10.1% of FocalTherics shares are held by insiders. Comparatively, 4.0% of SiBone shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, FocalTherics and FocalTherics both had 1 articles in the media. FocalTherics' average media sentiment score of 0.75 beat SiBone's score of 0.00 indicating that FocalTherics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SiBone has a net margin of -8.10% compared to FocalTherics' net margin of -41.47%. SiBone's return on equity of -9.56% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-41.47%	-137.61%	-40.62%
SiBone	-8.10%	-9.56%	-7.06%

FocalTherics presently has a consensus price target of $6.00, indicating a potential upside of 20.97%. SiBone has a consensus price target of $23.00, indicating a potential upside of 42.46%. Given SiBone's stronger consensus rating and higher probable upside, analysts plainly believe SiBone is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

SiBone beats FocalTherics on 11 of the 14 factors compared between the two stocks.

How does FocalTherics compare to Beta Bionics?

FocalTherics (NASDAQ:FOCL) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Beta Bionics had 4 more articles in the media than FocalTherics. MarketBeat recorded 5 mentions for Beta Bionics and 1 mentions for FocalTherics. Beta Bionics' average media sentiment score of 1.06 beat FocalTherics' score of 0.75 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FocalTherics has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.64	-$29.25M	-$0.81	N/A
Beta Bionics	$100.25M	6.15	-$73.20M	-$1.51	N/A

FocalTherics presently has a consensus target price of $6.00, indicating a potential upside of 20.97%. Beta Bionics has a consensus target price of $19.70, indicating a potential upside of 42.34%. Given Beta Bionics' stronger consensus rating and higher possible upside, analysts plainly believe Beta Bionics is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

FocalTherics has a net margin of -41.47% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-41.47%	-137.61%	-40.62%
Beta Bionics	-60.27%	-23.00%	-20.55%

Summary

Beta Bionics beats FocalTherics on 10 of the 16 factors compared between the two stocks.

How does FocalTherics compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and FocalTherics (NASDAQ:FOCL) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Spyglass Pharma currently has a consensus target price of $45.00, suggesting a potential upside of 132.38%. FocalTherics has a consensus target price of $6.00, suggesting a potential upside of 20.97%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe Spyglass Pharma is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Spyglass Pharma has a net margin of 0.00% compared to FocalTherics' net margin of -41.47%. Spyglass Pharma's return on equity of 0.00% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
FocalTherics	-41.47%	-137.61%	-40.62%

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, FocalTherics had 1 more articles in the media than Spyglass Pharma. MarketBeat recorded 1 mentions for FocalTherics and 0 mentions for Spyglass Pharma. FocalTherics' average media sentiment score of 0.75 beat Spyglass Pharma's score of 0.00 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Overall Sentiment
Spyglass Pharma	Neutral
FocalTherics	Positive

Spyglass Pharma has higher earnings, but lower revenue than FocalTherics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
FocalTherics	$70.53M	2.64	-$29.25M	-$0.81	N/A

Summary

Spyglass Pharma beats FocalTherics on 6 of the 11 factors compared between the two stocks.

How does FocalTherics compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and FocalTherics (NASDAQ:FOCL) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Tactile Systems Technology has a net margin of 5.91% compared to FocalTherics' net margin of -41.47%. Tactile Systems Technology's return on equity of 9.70% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	5.91%	9.70%	7.53%
FocalTherics	-41.47%	-137.61%	-40.62%

83.4% of Tactile Systems Technology shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 2.1% of Tactile Systems Technology shares are held by insiders. Comparatively, 10.1% of FocalTherics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tactile Systems Technology currently has a consensus price target of $38.60, suggesting a potential upside of 43.10%. FocalTherics has a consensus price target of $6.00, suggesting a potential upside of 20.97%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Tactile Systems Technology is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, FocalTherics had 1 more articles in the media than Tactile Systems Technology. MarketBeat recorded 1 mentions for FocalTherics and 0 mentions for Tactile Systems Technology. FocalTherics' average media sentiment score of 0.75 beat Tactile Systems Technology's score of 0.00 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tactile Systems Technology	Neutral
FocalTherics	Positive

Tactile Systems Technology has higher revenue and earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$343.52M	1.77	$19.09M	$0.88	30.65
FocalTherics	$70.53M	2.64	-$29.25M	-$0.81	N/A

Summary

Tactile Systems Technology beats FocalTherics on 12 of the 16 factors compared between the two stocks.

Get FocalTherics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FOCL vs. The Competition

Export

Metric	FocalTherics	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$185.90M	$2.68B	$4.36B	$12.17B
Dividend Yield	N/A	N/A	10.94%	5.81%
P/E Ratio	-6.12	13.26	22.08	24.06
Price / Sales	2.64	360.29	211.05	110.93
Price / Cash	N/A	7.99	41.09	37.84
Price / Book	9.54	6.01	18.42	6.54
Net Income	-$29.25M	$7.39M	$115.37M	$336.78M
7 Day Performance	4.42%	-4.16%	-0.35%	0.00%
1 Month Performance	N/A	-8.38%	-1.65%	0.99%
1 Year Performance	N/A	11.11%	12.84%	32.07%

FocalTherics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FOCL FocalTherics	3.6455 of 5 stars	$4.96 +1.2%	$6.00 +21.0%	N/A	$185.90M	$70.53M	N/A	230
CBLL CeriBell	2.6529 of 5 stars	$18.10 -2.6%	$22.20 +22.7%	+1.5%	$688.61M	$89.06M	N/A	N/A
SIBN SiBone	1.8036 of 5 stars	$15.29 +1.1%	$23.00 +50.5%	-3.5%	$677.45M	$200.93M	N/A	350
BBNX Beta Bionics	3.5437 of 5 stars	$13.66 -5.0%	$19.70 +44.2%	-23.4%	$612.48M	$100.25M	N/A	294	Gap Down
SGP Spyglass Pharma	N/A	$18.23 -3.8%	$45.00 +146.9%	N/A	$607.81M	N/A	N/A	65

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FOCL) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FocalTherics (FOCL) Competitors

FOCL vs. CBLL, SIBN, BBNX, SGP, and TCMD

How does FocalTherics compare to CeriBell?

Summary

How does FocalTherics compare to SiBone?

Summary

How does FocalTherics compare to Beta Bionics?

Summary

How does FocalTherics compare to Spyglass Pharma?

Summary

How does FocalTherics compare to Tactile Systems Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FocalTherics (FOCL) Competitors

FOCL vs. CBLL, SIBN, BBNX, SGP, and TCMD

How does FocalTherics compare to CeriBell?

Does the media favor FOCL or CBLL?

Is FOCL or CBLL more profitable?

Do analysts prefer FOCL or CBLL?

Do insiders & institutionals hold more shares of FOCL or CBLL?

Which has stronger valuation & earnings, FOCL or CBLL?

Summary

How does FocalTherics compare to SiBone?

Which has better earnings and valuation, FOCL or SIBN?

Do insiders and institutionals believe in FOCL or SIBN?

Does the media refer more to FOCL or SIBN?

Is FOCL or SIBN more profitable?

Do analysts rate FOCL or SIBN?

Summary

How does FocalTherics compare to Beta Bionics?

Do institutionals and insiders believe in FOCL or BBNX?

Does the media prefer FOCL or BBNX?

Which has better valuation & earnings, FOCL or BBNX?

Do analysts prefer FOCL or BBNX?

Is FOCL or BBNX more profitable?

Summary

How does FocalTherics compare to Spyglass Pharma?

Do analysts recommend SGP or FOCL?

Is SGP or FOCL more profitable?

Do insiders & institutionals hold more shares of SGP or FOCL?

Does the media favor SGP or FOCL?

Which has better valuation and earnings, SGP or FOCL?

Summary

How does FocalTherics compare to Tactile Systems Technology?

Is TCMD or FOCL more profitable?

Do insiders and institutionals have more ownership in TCMD or FOCL?

Do analysts recommend TCMD or FOCL?

Does the media refer more to TCMD or FOCL?

Which has better earnings & valuation, TCMD or FOCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools